Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 248

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Open access
Hamada, Yukihiro, Tokimatsu, Issei, Mikamo, Hiroshige, Kimura, Masao, Seki, Masafumi, Takakura, Shunji, Ohmagari, Norio, Takahashi, Yoshiko, Kasahara, Kei, Matsumoto, Kazuaki, Okada, Kenji, Igarashi, Masahiro, Kobayashi, Masahiro, Mochizuki, Takahiro, Nishi, Yoshifumi, Tanigawara, Yusuke, Kimura, Toshimi, Takesue, Yoshio · 2013 · Journal of Infection and Chemotherapy

Abstract

enzyme CYP2C19 is one of the major determinants of the VRCZ blood level.The frequency of poor metabolizers (PM), with defective or diminished metabolic capacity, is higher among Japanese patients.Variability in the plasma concentrations, arising from these previously mentioned aspects, may lead to variability in efficacy or toxicity.Determining the plasma concentration is indicated in some situations to guide dosing and to individualize and improve the treatment options, resulting in a better therapeutic outcome or fewer side effects.In this guideline, we review the factors that influence the VRCZ pharmacokinetic profile, the data supporting exposure-effect and exposure-toxicity relationships that make broad recommendations for therapeutic drug monitoring difficult for VRCZ, and provide indications for which therapeutic drug monitoring is reasonable based on currently available data (for example, in children).We also outline ways in which the existing problems can be solved. MethodsThe practice guidelines for therapeutic drug monitoring (TDM) of VRCZ were reviewed by a practice guideline committee, consisting of 18 experts in the field of TDM (Expert Panel) convened from the Japanese Society of Chemotherapy (JSC) and the Japanese Society of Therapeutic Drug Monitoring (JSTDM).The Expert Panel reviewed papers published since 2000 and additionally analyzed data before 1999, if necessary.Computerized PUBMED searches of the English-language literature and Igaku-Chuo-Zasshi searches of the Japanese-language literature were performed using the terms ''voriconazole'' and ''therapeutic drug monitoring'' and focused mainly on human studies; however, animal studies and in vitro data were included if necessary.The committee specifically looked for existing randomized clinical trials and existing meta-analysis using a general database (i.e., MEDLINE, EMBASE), and the Cochrane Library (both The Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effectiveness); however, few randomized clinical trials and meta-analyses were available and many recommendations were developed from observational studies or small case studies.To evaluate evidence regarding TDM, the Expert Panel followed the Canadian Task Force recommendations [3], which included a systematic weighting of the quality of the evidence and a graded recommendation according to the Minds classification (Table 1).The Expert Panel met in person on 7 occasions and by E-mail via mailing lists on 533 occasions.The draft guidelines for the executive summary were placed on the homepage of the JSC and JSTDM.Feedback from external public comments was obtained between April 9, 2012, and May 8, 2012.The guidelines for the Japanese version were approved by the JSC and JSTDM Board of Directors and were published in the Japanese Journal of Chemotherapy in June 2012.All the members of the practice guideline committee complied with the JSC policy on conflicts of interest, which requires the disclosure of any financial or other interest that Table 1 Grading system for ranking recommendations and evidence level adopted in the guideline Category, grade Definition Strength of recommendation A Good evidence to support a recommendation for use B Moderate evidence to support a recommendation for use C1 Recommendation for use regardless of poor evidence C2 Poor evidence to support a recommendation for use D Good-to-moderate evidence to support a recommendation against use Quality of evidence I Evidence from C1 properly randomized, controlled trial II Evidence from C1 well-designed clinical trial, without randomization from cohort or case-controlled analytical studies, multiple time-series, or dramatic results from uncontrolled experiments.III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10156-013-0607-8

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 248

Metadata

Authors
Hamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., Okada, K., Igarashi, M., Kobayashi, M., Mochizuki, T., Nishi, Y., Tanigawara, Y., Kimura, T., & Takesue, Y.
Venue
Journal of Infection and Chemotherapy
Publisher
Elsevier BV
Published
2013
Volume
19
Issue
3
Pages
381-392
ISSN
1341-321X (ISSN-L)
OpenAlex
W2106444474
Cited by
248
References
6
FWCI
11.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. https://app.cochat.ai/papers/10.1007/s10156-013-0607-8
The paper
Hamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., Okada, K., Igarashi, M., Kobayashi, M., Mochizuki, T., Nishi, Y., Tanigawara, Y., Kimura, T., & Takesue, Y. (2013). Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy. https://doi.org/10.1007/s10156-013-0607-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.